 Source: Justin Zelin 121622 The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report. Adicet Bio Inc. ACET:NASDAQ presented encouraging data from its ongoing Phase 1 trial evaluating the companys lead therapeutic ADI-001, its chimeric antigen receptor CAR T-cell therapy, in large B-cell ...... 